Your search has returned a large number of results. Try searching for a more specific term or phrase.

INTELLECTUAL PROPERTY

Our Science INTELLECTUAL PROPERTY Alnylam protects its Intellectual Property (IP) with fundamental, chemistry, delivery, and target patents and patent applications covering the design, development and commercialization of RNAi therapeutics as…

SCIENTIFIC ADVISORY BOARD

Our Science SCIENTIFIC ADVISORY BOARD Our Scientific Advisory Board The scientific advisors and founders of Alnylam are among the world’s leaders in RNAi research as well as broad aspects of medical research. Learn more about the…

DELIVERY PLATFORMS

Our Science DELIVERY PLATFORMS Our RNA interference (RNAi) therapeutics utilize two distinct approaches to enable delivery of small interfering RNA (siRNA) to target tissues—lipid nanoparticles (LNPs) and conjugates. We are…

PIPELINE

Our Science OUR PIPELINE Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an entirely new class of medicines that is disrupting…

OUR PRODUCTS

Our Products OUR PRODUCTS Approved for Use in the United States

OUR SCIENCE

Our Science OUR SCIENCE Pioneering RNA interference (RNAi) Therapeutics RNAi therapeutics are an innovative class of gene silencing medicines based on RNA interference (RNAi)—a breakthrough discovery in understanding how genes are regulated…, *out-licensed

Investigator Initiated Studies

Our Company ALNYLAM MEDICAL RESEARCH  INVESTIGATOR-INITIATED STUDIES Investigator Initiated Studies (IIS) are unsolicited research originating from an external researcher, institution, or organization. These studies may be referred…, Important note on disclosure: Alnylam is committed to transparency in its interactions with healthcare professionals and healthcare organizations/institutions consistent with applicable laws and/or codes of practice applicable to the…

CORPORATE RESPONSIBILITY

Our Company CORPORATE RESPONSIBILITY Accepting Challenges to Improve the Health of Humanity Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” our approach to Corporate Responsibility informs our business…

Patient Philosophy

Our Company OUR PATIENT ACCESS PHILOSOPHY Our Commitment to Patients and Partners Throughout our 20+ year journey in developing RNAi therapeutics, we have remained focused on keeping patients at the center of everything we do. Beyond…

Our Leadership

Our Company OUR LEADERSHIP The strength of our leadership has always been one of Alnylam’s greatest assets. Experience, tenacity, accountability, people-focus and a commitment to the greater good are leadership traits we value and they’re…, Board of Directors The Alnylam Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization, and strategy to our efforts in developing RNAi (RNA…